Xiaohui He - Publications

Affiliations: 
2000 Chemistry University of Wisconsin-Milwaukee, Milwaukee, WI 

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Shi Y, Li J, Xu J, Sun Y, Wang L, Cheng Y, Liu W, Sun G, Chen Y, Bai L, Zhang Y, He X, Luo Y, Wang Z, Liu Y, et al. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. Cancer Communications (London, England). 39: 28. PMID 31126331 DOI: 10.1186/s40880-019-0374-8  0.36
2019 Han Y, Yang J, Liu P, He X, Zhang C, Zhou S, Zhou L, Qin Y, Song Y, Sun Y, Shi Y. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. The Oncologist. PMID 30952824 DOI: 10.1634/theoncologist.2018-0361  0.36
2018 Hu S, Song Y, Sun X, Su L, Zhang W, Jia J, Bai O, Yang S, Liang R, Li X, Zhang H, Gao Y, Zhang W, Xiao X, Bao H, ... ... He X, et al. Primary breast diffuse large B-cell lymphoma in the rituximab era: therapeutic modalities and patterns of failure. Cancer Science. PMID 30302857 DOI: 10.1111/cas.13828  0.36
2018 Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. The Lancet. Oncology. PMID 30213452 DOI: 10.1016/S1470-2045(18)30495-9  0.52
2018 Zhou S, Zuo L, He X, Pi J, Jin J, Shi Y. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy. Thoracic Cancer. PMID 30152052 DOI: 10.1111/1759-7714.12827  0.36
2016 Sun H, Wan H, Zhang L, He X. [Clinical observation of blood-letting to reduce pressure plus electroacupuncture for acute scapulohumeral periarthritis]. Zhongguo Zhen Jiu = Chinese Acupuncture & Moxibustion. 36: 933-937. PMID 29231387 DOI: 10.13703/j.0255-2930.2016.09.010  0.52
2016 Qi F, Dong M, He X, Li Y, Wang W, Liu P, Yang J, Gui L, Zhang C, Yang S, Zhou S, Shi Y. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified. Annals of Hematology. PMID 27858107 DOI: 10.1007/s00277-016-2877-6  0.36
2016 Wang Q, Qin Y, Zhou S, He X, Yang J, Kang S, Liu P, Yang S, Zhang C, Gui L, Sun Y, Shi Y. Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. Oncotarget. PMID 27750215 DOI: 10.18632/oncotarget.12663  0.36
2016 Gui L, Han X, He X, Song Y, Yao J, Yang J, Liu P, Qin Y, Zhang S, Zhang W, Gai W, Xie L, Shi Y. Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 28: 197-208. PMID 27199517 DOI: 10.21147/j.issn.1000-9604.2016.02.07  0.36
2016 Jia B, Hu S, Yang J, Zhou S, Liu P, Qin Y, Gui L, Yang S, Lin H, Zhang C, Xing P, Wang L, Dong M, Zhou L, Sun Y, ... He X, et al. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. Hematology (Amsterdam, Netherlands). 1-6. PMID 27077778 DOI: 10.1080/10245332.2016.1152084  0.36
2016 Yang S, He XH, Liu P, Zhou SY, Dong M, Qin Y, Yang JL, Zhang CG, Han XH, Shi YK. [Duration of filgrastim prophylaxis for chemotherapy-induced neutropenia and its predictors]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 38: 69-72. PMID 26796810  0.36
2015 Huang Y, Zhou SY, He XH, Gui L, Yang JL, Liu P, Qin Y, Zhang ZG, Xing PY, Yang S, Wang L, Zhou LQ, Dong M, Sun Y, Shi YK. [Clinicopathological characteristics and prognostic analysis of primary intestinal diffuse large B-cell lymphoma]. Zhonghua Yi Xue Za Zhi. 95: 3895-8. PMID 27122208 DOI: 10.3760/cma.j.issn.0376-2491.2015.48.004  0.36
2015 Hu S, He X, Dong M, Jia B, Zhou S, Yang J, Yang S, Zhang C, Liu P, Qin Y, Gui L. [Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 37: 632-6. PMID 26714607  0.36
2015 Kang S, Qin Y, He X, Zhou S, Han X, Liu P, Dong M, Zhou L, Yang J, Yang S, Zhang C, Gui L, Shi Y. [Infection status and prognostic significance analysis of Epstein-Barr virus in 207 cases with newly diagnosed Hodgkin's lymphoma]. Zhonghua Yi Xue Za Zhi. 95: 2594-8. PMID 26711606  0.36
2015 Wang J, Wu Y, Dong M, He X, Wang Z, Li J, Wang Y. Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer. Anti-Cancer Drugs. PMID 26633888 DOI: 10.1097/CAD.0000000000000323  0.32
2015 Jia B, Shi Y, Kang S, Yang S, Hu S, Li Y, Dong M, Wang W, Yang J, Zhou L, Liu P, Zhou S, Qin Y, Gui L, Zhang C, ... ... He X, et al. Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma. Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 27: 516-23. PMID 26543339 DOI: 10.3978/j.issn.1000-9604.2015.10.04  0.36
2015 Shi Y, Zhou P, Han X, He X, Zhou S, Liu P, Yang J, Zhang C, Gui L, Qin Y, Yang S, Zhao L, Yao J, Zhang S. Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma. Chinese Journal of Cancer. 34: 52. PMID 26370464 DOI: 10.1186/s40880-015-0045-3  0.36
2015 Gui L, Shi Y, He X, Zhou L, Dong M, Zhou S, Yuan P, Liu P, Yang J, Zhang C, Qin Y, Yang S. [Clinicopathological features and outcomes: analysis of 21 cases of lymphoma in pregnancy]. Zhonghua Yi Xue Za Zhi. 95: 425-9. PMID 25916778  0.36
2015 Shi Y, Zhou S, He X, Han X, Wu S, Pan F, Liu P, Liu Y, Lei Y, Zhang H, Yang J, Qin Y, Zhang C, Yang S, Zhao L, et al. Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis. Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 27: 66-73. PMID 25717228 DOI: 10.3978/j.issn.1000-9604.2015.02.04  0.36
2015 Yang J, Shi Y, He X, Dong M, Zhang C, Liu P, Zhou S, Qin Y, Gui L, Yang S, Sun Y. A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma. Leukemia & Lymphoma. 1-4. PMID 25563558 DOI: 10.3109/10428194.2014.999323  0.36
2015 Mo H, Shi Y, Han X, Zhou S, He X, Liu P, Yang J, Zhang C, Yang S, Qin Y, Gui L, Shi Y, Yao J, Zhao L, Zhang S. Absolute monocyte count is a prognostic indicator in a patient with diffuse large B-cell lymphoma after autologous peripheral blood stem cell transplant. Leukemia & Lymphoma. 56: 515-7. PMID 24844360 DOI: 10.3109/10428194.2014.920504  0.36
2014 Yang J, Shi Y, He X, Zhou S, Dong M, Liu P, Zhou L, Zhang C, Qin Y, Yang S, Gui L. [Efficacy analysis of different follow-up methods in detecting first recurrence of lymphoma]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 36: 933-8. PMID 25623770  0.36
2014 Zhou P, Shi Y, He X, Zhou S, Liu P, Dong M, Qin Y, Yang J, Zhang C, Zhou L, Yang S, Gui L. [Clinical features and prognostic analysis of mantle cell lymphoma patients]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 36: 928-32. PMID 25623769  0.36
2014 Han X, Wang J, Zhang N, Yao J, Feng Y, Li D, Liu P, Yang J, Zhou S, Qin Y, Yang S, Gui L, He X, Shi Y. The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma. Leukemia Research. 38: 1291-8. PMID 25287608 DOI: 10.1016/j.leukres.2014.09.006  0.36
2014 Jia B, Shi Y, Dong M, Feng F, Yang S, Lin H, Zhou L, Zhou S, Chen S, Yang J, Liu P, Qin Y, Zhang C, Gui L, Wang L, ... ... He X, et al. Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma. Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 26: 459-65. PMID 25232220 DOI: 10.3978/j.issn.1000-9604.2014.08.12  0.36
2014 Yang J, Shi Y, He X, Zhou S, Dong M, Liu P, Zhang C, Qin Y, Yang S, Gui L. [Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 36: 137-40. PMID 24796464  0.36
2014 Luo Y, Shi Y, Xing P, Wang L, Feng Y, Han X, He X. Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study. Molecular and Clinical Oncology. 2: 87-92. PMID 24649313 DOI: 10.3892/mco.2013.199  0.32
2014 Qin X, Peng F, Yang F, He X, Huang H, Luo D, Yang J, Wang S, Liu H, Peng L, Li Y. Growth of semiconducting single-walled carbon nanotubes by using ceria as catalyst supports. Nano Letters. 14: 512-7. PMID 24392872 DOI: 10.1021/nl403515c  0.32
2012 Han X, Ma L, Zhao L, He X, Liu P, Zhou S, Yang J, Qin Y, Yang S, Yao J, Shi Y. Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study. Journal of Clinical Apheresis. 27: 64-74. PMID 22298390 DOI: 10.1002/jca.21204  0.36
2011 Wang C, He X, Zhou B, Li J, Li B, Qian W, Hou S, Wang H, Shi Y, Guo Y. Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. Mabs. 3: 67-75. PMID 21051930  0.32
2009 Niu Y, Shi Y, Zhou S, Pan F, Wu S, Liu P, Yang J, Han X, He X. Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma. International Journal of Hematology. 89: 106-12. PMID 19067117 DOI: 10.1007/s12185-008-0217-x  0.36
2007 Shi Y, He X, Yang S, Ai B, Zhang C, Huang D, Dong M, Liu P, Zhou S, Han X. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study. Chemotherapy. 53: 44-50. PMID 17202811 DOI: 10.1159/000098418  0.36
2002 Zhou A, Shi Y, Feng F, Lu S, He X, Han X. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 24: 467-70. PMID 12485501  0.32
2002 Wang J, Zhang B, Yang S, He X, Han J, Li B, Hou L. Development of a monoclonal antibody for neutralization of human telomerase activity. Hybridoma and Hybridomics. 21: 295-300. PMID 12193283 DOI: 10.1089/153685902760213912  0.32
2002 Shi Y, Han X, He X, Yang J, Liu P. [Mobilization of autologous peripheral blood stem cells by cytosine arabinoside combined with recombinant human granulocyte colony-stimulating factor]. Zhonghua Yi Xue Za Zhi. 82: 462-6. PMID 12133516  0.36
Show low-probability matches.